Cancer News and Research

Latest Cancer News and Research

Scientific evidence supports benefits of sunscreen usage to prevent skin cancer

The American Academy of Dermatology today reiterated the safety and effectiveness of sunscreens to protect against the damaging effects from exposure to ultraviolet (UV) radiation. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cancer.

24 May 2011

Some African descent men may have higher genetic risk of developing prostate cancer

Some men of African descent may have a higher genetic risk of developing prostate cancer, according to research conducted at the Keck School of Medicine of the University of Southern California.

24 May 2011

Fluorinated glucosamine blocks synthesis of key sugar linked to skin inflammation, cancer progression

Charles J. Dimitroff, MS, PhD and colleagues in the Dimitroff Lab at Brigham and Women's Hospital, have developed a fluorinated analog of glucosamine, which, in a recent study, has been shown to block the synthesis of key carbohydrate structures linked to skin inflammation and cancer progression. These findings appear in the April 14, 2011, issue of the Journal of Biological Chemistry.

24 May 2011

Exosome Diagnostics announces expansion of scientific advisory board

Exosome Diagnostics, a leading developer of biofluid based molecular diagnostic tests for use in personalised medicine, today announced the appointments of Bob Carter MD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB).

24 May 2011

Researchers discover protein switch that can trigger heart failure

Researchers at the Peter Munk Cardiac Centre discovered a protein switch which can trigger a cascade of events leading to heart failure, pointing to a new direction for drug development.

24 May 2011

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

Altor BioScience Corporation announced today that the National Heart Lung and Blood Institute has awarded Altor a Small Business Innovation Research Phase II Competing Renewal Grant. The award of over $3.18 MM over three years will support Altor's efforts to complete a second Phase 2 clinical trial using ALT-836, an antibody-based tissue factor antagonist, as a therapy to treat patients with infection-induced acute lung injury/acute respiratory distress syndrome.

24 May 2011

Swedish Medical Center implements Aegis' physician relationship management program

Swedish Medical Center, the largest nonprofit healthcare provider in the Greater Seattle area, has selected tools provided by Aegis Health Group to enhance its physician relationship management program. Aegis' custom-designed solution includes its proprietary contact management software PRISM as well as sales training and program development support.

24 May 2011

Skagit Valley Hospital joins Premier healthcare alliance and saves more than $1M annually

Skagit Valley Hospital of Mount Vernon, Wash., saved more than $1 million by joining the Premier healthcare alliance.

24 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Novel hepatitis C-like virus discovered in dogs

In a study to be published online this week in the Proceedings of the National Academy of Sciences, researchers report the discovery of a novel hepatitis C-like virus in dogs. The identification and characterization of this virus gives scientists new insights into how hepatitis C in humans may have evolved and provides scientists renewed hope to develop a model system to study how it causes disease.

24 May 2011

Shave biopsies accurate in initial diagnosis of suspicious skin lesions

A shave biopsy is a reasonably safe and accurate method for the initial diagnosis of melanoma, according to a study published in the April issue of the Journal of the American College of Surgeons. In the past, some physicians have criticized shave biopsies for not providing accurate T (tumor) stage information, thereby complicating treatment planning.

24 May 2011

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

A protein isolated from beneficial bacteria found in yogurt and dairy products could offer a new, oral therapeutic option for inflammatory bowel disorders, suggests a study led by Vanderbilt University Medical Center researcher Fang Yan, M.D., Ph.D.

24 May 2011

Variant of obesity gene may increase breast cancer risk

New research aimed to better identify the genetic factors that lead to breast cancer has uncovered a link between the fat mass and obesity associated gene and a higher incidence of breast cancer.

24 May 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Researchers from Mount Sinai School of Medicine have discovered a protein signaling pathway that becomes hyperactivated in human sarcoma cells, suggesting that medications to inhibit this pathway may be effective in the treatment of human sarcomas. The research is published in the current issue of the journal Cancer Cell.

24 May 2011

Long-term, regular acetaminophen use may be associated with lower prostate cancer risk

A new study from American Cancer Society researchers finds use of 30 tablets a month or more of acetaminophen for five or more years was associated with an estimated 38% lower risk of prostate cancer. The study appears in Cancer Epidemiology, Biomarkers and Prevention and is one of only two studies of prostate cancer to date that have examined the association with acetaminophen use that was both long-term and regular.

24 May 2011

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

The U.S. Food and Drug Administration today approved Incivek treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Terminally ill missing out on palliative care: Survey reports

According to two new surveys, increased hospital admissions in the last three months of life could be of little benefit to dying people and are in contrast to the wishes of many.

23 May 2011

PolyPid announces new drug delivery system and an innovative biodegradable bone void filler

PolyPid, a developer of innovative drug carriers, announced today the company’s flagship platform – PolyPid. PolyPid is a new, innovative family of drug carriers, based on a fusion between two known drug delivery systems: polymers and lipid-based systems. The new drug carriers enable long-lasting and controlled release of therapeutic drugs. The revolutionary, patented carrier can be tailored to almost any drug – small molecules, peptides, protein and nucleic acids-based drugs. The formulations can be pre-planned in order to achieve the desired release rate of the drug/s and the optimal duration, which can last up to several months.

23 May 2011

Cancer News and Research

Latest Cancer News and Research

Scientific evidence supports benefits of sunscreen usage to prevent skin cancer

Some African descent men may have higher genetic risk of developing prostate cancer

Fluorinated glucosamine blocks synthesis of key sugar linked to skin inflammation, cancer progression

Exosome Diagnostics announces expansion of scientific advisory board

Researchers discover protein switch that can trigger heart failure

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

Swedish Medical Center implements Aegis' physician relationship management program

Skagit Valley Hospital joins Premier healthcare alliance and saves more than $1M annually

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Novel hepatitis C-like virus discovered in dogs

Shave biopsies accurate in initial diagnosis of suspicious skin lesions

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

Variant of obesity gene may increase breast cancer risk

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

Mount Sinai researchers identify protein signaling hyperactivity in human sarcoma cells

Long-term, regular acetaminophen use may be associated with lower prostate cancer risk

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Terminally ill missing out on palliative care: Survey reports

PolyPid announces new drug delivery system and an innovative biodegradable bone void filler

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in